A multiprotein signaling complex sustains AKT and mTOR/S6K activity necessary for the survival of cancer cells undergoing stress
O. Y. Teran Pumar, M. R. Zanotelli, M.-c. J. Lin, R. R. Schmitt, K. S. Green, K. S. Rojas, I. Y. Hwang, R. A. Cerione, K. F. Wilson
Abstract
The ability of cancer cells to survive microenvironmental stresses is critical for tumor progression and metastasis; however, how they survive these challenges is not fully understood. Here, we describe a novel multiprotein complex (DockTOR) essential for the survival of cancer cells under stress, triggered by the GTPase Cdc42 and a signaling partner Dock7, which includes AKT, mTOR, and the mTOR regulators TSC1, TSC2, and Rheb. DockTOR enables cancer cells to maintain a low but critical mTORC2-dependent phosphorylation of AKT during serum deprivation by preventing AKT dephosphorylation through an interaction between phospho-AKT and the Dock7 DHR1 domain. This activity stimulates a Raptor-independent but Rapamycin-sensitive mTOR/S6K activity necessary for survival. These findings address long-standing questions of how Cdc42 signals result in mTOR activation and demonstrate how cancer cells survive conditions when growth factor-dependent activation of mTORC1 is off. Determining how cancer cells survive stress conditions could identify vulnerabilities that lead to new therapeutic strategies.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The mTORC1/S6K/PDCD4/eIF4A axis determines outcome of mitosis.
Mohamed Moustafa-Kamal, Thomas J. Kucharski, … Jose G. Teodoro·Cell ReportsPeer-reviewed·Oct 1, 2020
- Oncogenic Activation of AKT by MAPK6
- The Mixed Blessing of AMPK Signaling in Cancer Treatments
Mehrshad Sadria, Deokhwa Seo, Anita T. Layton·BMC CancerPeer-reviewed·Jan 25, 2022
- Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer
G. Zhao, G. Forn-Cuni, … E. B. Snaar·bioRxiv·Aug 14, 2023
- Alkaline intracellular pH activates AMPK-mTORC2 signaling to promote cell survival during growth factor limitation
D. Kazyken, S. I. Lentz, D. C. Fingar·bioRxiv·May 13, 2021
- Dynamic Modeling of Signal Transduction by mTOR Complexes in Cancer
Mohammadreza Dorvash, Mohammad Farahmandnia, … Iman Tavassoly·Journal of Theoretical BiologyPeer-reviewed·Sep 4, 2019